Cybin receives FDA approval for new in-human clinical trial

Mugglehead
By Rowan DunneJun 28, 2022, 10:13 pm324 pts
A renowned biopharmaceutical company has received a “may proceed” letter for its new clinical trial examining the effects of an altered psilocybin compound on mental health. On Monday, Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced that it had been granted Investigational New Drug (IND) application…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Snuneymuxw First Nation close to completing on-reserve cannabis facility in Nanaimo 64

Jungle Boys Opening 1st Arizona Dispensary in Phoenix 42

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.